Publication

Barton ME, et al. Bepranemab in prodromal-to-mild Alzheimer's disease: a phase 2 randomised trial. Lancet Neurology, 2026

PMID 43008775

Phase 2 RCT of intravenous bepranemab versus placebo in 466 adults aged 50–80 with prodromal-to-mild Alzheimer's disease. The primary endpoint, CDR-SB change at week 80, was not met. Sponsor: UCB.

1 news item

News about this publication

Scales

Identifiers

PMID
43008775
DOI
10.1016/S1474-4422(26)00357-1

Original sources

Details

Journal
Lancet Neurology
Year
2026

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.